| 1 |
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet
|
9 Mar 2016 |
2,823 |
| 2 |
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer Keating Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine
Open access |
15 Aug 2018 |
2,198 |
| 3 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 4 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
2,026 |
| 5 |
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
Armando E. Giuliano, Karla V. Ballman, Linda Mackie McCall et al. · JAMA
Open access |
12 Sep 2017 |
1,941 |
| 6 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 7 |
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Fadlo Raja Khuri, John J. Nemunaitis, Ian Ganly et al. · Nature Medicine
|
Aug 2000 |
1,109 |
| 8 |
Recommendations on the Use of 18 F-FDG PET in Oncology
James W. Fletcher, Benjamin Djulbegović, Heloisa Prado Soares et al. · Journal of Nuclear Medicine
Open access |
20 Feb 2008 |
1,108 |
| 9 |
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey et al. · Journal of Clinical Oncology
Open access |
28 Jan 2021 |
1,053 |
| 10 |
Carcinogenic human papillomavirus infection
MARK H. SCHIFFMAN, John Doorbar, Nicolas Wentzensen et al. · Nature Reviews Disease Primers
Review |
30 Nov 2016 |
1,036 |
| 11 |
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
Eric A. Klein, Donald Richards, Allen Lee Cohn et al. · Annals of Oncology
Open access |
24 Jun 2021 |
1,027 |
| 12 |
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
Paul David Brown, Shannon K. Pugh, Nadia N. Laack et al. · Neuro-Oncology
Open access |
16 Aug 2013 |
963 |
| 13 |
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert Louis Coleman et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
944 |
| 14 |
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza et al. · New England Journal of Medicine
Open access |
27 Mar 2023 |
865 |
| 15 |
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study
Charles S. Fuchs, John Lindsay Marshall, Edith Peterson Mitchell et al. · Journal of Clinical Oncology
|
18 Oct 2007 |
861 |
| 16 |
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Joyce A O'Shaughnessy, Cynthia Osborne, John Pippen et al. · New England Journal of Medicine
|
5 Jan 2011 |
817 |
| 17 |
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari et al. · The Lancet
Open access |
27 Jul 2017 |
697 |
| 18 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul Edward Goss, James N. Ingle, Kathleen I. Pritchard et al. · New England Journal of Medicine
Open access |
5 Jun 2016 |
656 |
| 19 |
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al. · The Lancet Oncology
|
12 Feb 2016 |
569 |
| 20 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa Ann Geller et al. · The Lancet Oncology
|
Apr 2019 |
545 |
| 21 |
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
Frank A. Scappaticci, Louis Fehrenbacher, Thomas H. Cartwright et al. · Journal of Surgical Oncology
|
2005 |
537 |
| 22 |
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Jennifer R. Brown et al. · New England Journal of Medicine
Open access |
13 Dec 2022 |
492 |
| 23 |
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Éric Pujade-Lauraine et al. · The Lancet Oncology
Open access |
15 Jun 2021 |
426 |
| 24 |
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Jennifer Keating Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology
Open access |
20 Aug 2020 |
412 |
| 25 |
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert Louis Coleman et al. · The Lancet Oncology
|
9 Apr 2021 |
410 |
| 26 |
Uterine Microbiota: Residents, Tourists, or Invaders?
James M. Baker, Dana Meredith Chase, Melissa M. Herbst‐Kralovetz · Frontiers in Immunology
Open access |
Mar 2018 |
409 |
| 27 |
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk et al. · Journal of Clinical Oncology
Open access |
6 Jun 2022 |
407 |
| 28 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
Joanne Lorraine Blum, V�ronique Dieras, Patricia Mucci Lo Russo et al. · Cancer
Open access |
2001 |
403 |
| 29 |
Evaluation of cell-free DNA approaches for multi-cancer early detection
Arash Jamshidi et al. · Cancer Cell
Open access |
17 Nov 2022 |
335 |
| 30 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology
Open access |
27 Feb 2019 |
313 |
| 31 |
Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Tanios Bekaii‐Saab, Rona D. Yaeger, Alexander I. Spira et al. · Journal of Clinical Oncology
Open access |
26 Apr 2023 |
306 |
| 32 |
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo et al. · Annals of Oncology
Open access |
2 Mar 2021 |
304 |
| 33 |
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk, Nicoletta Colombo, Amit M. Oza et al. · The Lancet Oncology
Open access |
4 Aug 2021 |
298 |
| 34 |
Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women
Paweł Łaniewski, Dominique Barnes, Alison Goulder et al. · Scientific Reports
Open access |
9 May 2018 |
296 |
| 35 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
Frankie Ann Holmes, Stephen E. Jones, Joyce O’Shaughnessy et al. · Annals of Oncology
Open access |
Jun 2002 |
294 |
| 36 |
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
M. D. Pegram, Tadeusz Pieńkowski, Donald W. Northfelt et al. · JNCI Journal of the National Cancer Institute
Open access |
18 May 2004 |
272 |
| 37 |
Dosimetric considerations for patients with HIP prostheses undergoing pelvic irradiation. Report of the AAPM Radiation Therapy Committee Task Group 63
Chester S. Reft, Rodica Alecu, Indra J. Das et al. · Medical Physics
Open access |
30 May 2003 |
257 |
| 38 |
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research
Open access |
14 May 2019 |
249 |
| 39 |
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
David Michael Waterhouse et al. · Journal of Clinical Oncology
Open access |
10 Sep 2020 |
247 |
| 40 |
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer
Kathleen M. Schmeler et al. · International Journal of Gynecological Cancer
Open access |
7 Sep 2021 |
240 |
| 41 |
Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer Patients
Fadlo Raja Khuri, J. Jack Lee, Scott Michael Lippman et al. · JNCI Journal of the National Cancer Institute
|
4 Apr 2006 |
239 |
| 42 |
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M. Tolaney et al. · Journal of Clinical Oncology
Open access |
18 May 2021 |
235 |
| 43 |
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology
Open access |
6 Mar 2018 |
230 |
| 44 |
Obesity and Associated Comorbidities in People and Companion Animals: A One Health Perspective
Marjorie L. Chandler, Solveig Argeseanu Cunningham, Erik Lund et al. · Journal of Comparative Pathology
Open access |
28 Apr 2017 |
219 |
| 45 |
A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Kathy Rock, Orla McArdle, Patrick M. Forde et al. · British Journal of Radiology
Open access |
6 Feb 2012 |
203 |
| 46 |
Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer
Willemien van de Water, Christos J. Markopoulos, Cornelis J.�H. van de Velde et al. · JAMA
Open access |
7 Feb 2012 |
199 |
| 47 |
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M. del Campo et al. · Journal of Clinical Oncology
Open access |
7 Jun 2019 |
196 |
| 48 |
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
David M. O'Malley, Maryna Neffa, Bradley J. Monk et al. · Journal of Clinical Oncology
Open access |
21 Dec 2021 |
192 |
| 49 |
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma
Hideki Makinoshima, Masahiro Takita, Koichi Saruwatari et al. · Journal of Biological Chemistry
Open access |
29 May 2015 |
192 |
| 50 |
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Lajos Pusztai, Carsten Denkert, Joyce A O'Shaughnessy et al. · Annals of Oncology
Open access |
16 Feb 2024 |
171 |